{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:13:30Z","timestamp":1792084410863,"version":"4.4.0"},"reference-count":20,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["304985"],"award-info":[{"award-number":["304985"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["313011AFG5"],"award-info":[{"award-number":["313011AFG5"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,9,29]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Ochronotic spondyloarthropathy represents one of the main clinical manifestations of alkaptonuria (AKU); however, prospective data and description of the effect of nitisinone treatment are lacking.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with AKU aged 25 years or older were randomly assigned to receive either oral nitisinone 10\u2009mg\/day (N=69) or no treatment (N=69). Spine radiographs were recorded yearly at baseline, 12, 24, 36 and 48 months, and the images were scored for the presence of intervertebral space narrowing, soft tissue calcifications, vacuum phenomena, osteophytes\/hyperostosis and spinal fusion in the cervical, thoracic and lumbosacral segment at each of the time points.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, narrowing of the intervertebral spaces, the presence of osteophytes\/hyperostosis and calcifications were the three most frequent radiographic features in AKU. The rate of progression of the five main features during the 4\u2009years, ranked from the highest to lowest was as follows: intervertebral spaces narrowing, calcifications, vacuum phenomena, osteophytes\/hyperostosis and fusions. The rate of progression did not differ between the treated and untreated groups in any of the five radiographic parameters except for a slower rate of progression (sum of all five features) in the treatment group compared with the control group (0.45 (1.11) nitisinone vs 0.74 (1.11) controls, p=0.049) in the thoracic segment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The present study shows a relatively slow but significant worsening of radiographic features in patients with AKU over 4\u2009years. Our results demonstrate a modest beneficial effect of 10\u2009mg\/day of nitisinone on the slowly progressing spondylosis in AKU during the relatively limited follow-up time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01916382\">NCT01916382<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002422","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T09:57:15Z","timestamp":1666346235000},"page":"e002422","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01916382","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1747-7150","authenticated-orcid":false,"given":"Richard","family":"Imrich","sequence":"first","affiliation":[{"name":"Institute of Clinical and Translational Research, Biomedical Research Center Slovak Academy of Sciences, Bratislava, Slovakia"},{"name":"National Institute of Rheumatic Diseases, Pie\u0161\u0165any, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Sedl\u00e1kov\u00e1","sequence":"additional","affiliation":[{"name":"National Institute of Rheumatic Diseases, Pie\u0161\u0165any, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ria","family":"\u00dalehlov\u00e1","sequence":"additional","affiliation":[{"name":"National Institute of Rheumatic Diseases, Pie\u0161\u0165any, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Gornall","sequence":"additional","affiliation":[{"name":"Liverpool Cancer Trials Unit, Liverpool, Lancashire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Jackson","sequence":"additional","affiliation":[{"name":"Liverpool Cancer Trials Unit, Liverpool, Lancashire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Olsson","sequence":"additional","affiliation":[{"name":"Garriguella AB, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Rudebeck","sequence":"additional","affiliation":[{"name":"OnPoint Sciences AB, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Gallagher","sequence":"additional","affiliation":[{"name":"Musculoskeletal Biology, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O\u013ega","family":"Luk\u00e1\u010dov\u00e1","sequence":"additional","affiliation":[{"name":"National Institute of Rheumatic Diseases, Pie\u0161\u0165any, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Mlyn\u00e1rikov\u00e1","sequence":"additional","affiliation":[{"name":"National Institute of Rheumatic Diseases, Pie\u0161\u0165any, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Stan\u010d\u00edk","sequence":"additional","affiliation":[{"name":"National Institute of Rheumatic Diseases, Pie\u0161\u0165any, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Vrt\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"National Institute of Rheumatic Diseases, Pie\u0161\u0165any, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Z\u00e1\u0148ov\u00e1","sequence":"additional","affiliation":[{"name":"National Institute of Rheumatic Diseases, Pie\u0161\u0165any, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Za\u0165kov\u00e1","sequence":"additional","affiliation":[{"name":"Institute of Clinical and Translational Research, Biomedical Research Center Slovak Academy of Sciences, Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Arnoux","sequence":"additional","affiliation":[{"name":"Hopital Necker-Enfants Malades, Paris, \u00cele-de-France, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Rovensk\u00fd","sequence":"additional","affiliation":[{"name":"National Institute of Rheumatic Diseases, Pie\u0161\u0165any, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Luangrath","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Bygott","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Khedr","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry and Metabolic Medicine, Royal Liverpool University Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshminarayan R","family":"Ranganath","sequence":"additional","affiliation":[{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2025090312090735000_8.2.e002422.1","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1997.4805"},{"key":"2025090312090735000_8.2.e002422.2","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2015.60"},{"key":"2025090312090735000_8.2.e002422.3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41431-019-0354-0","article-title":"Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and genotype-phenotype correlations in the largest cohort of patients with AKU","volume":"27","author":"Ascher","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"2025090312090735000_8.2.e002422.4","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/jimd.12152","article-title":"Ochronotic pigmentation is caused by homogentisic acid and is the key event in alkaptonuria leading to the destructive consequences of the disease-A review","volume":"42","author":"Ranganath","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"2025090312090735000_8.2.e002422.5","doi-asserted-by":"publisher","DOI":"10.1086\/321209"},{"key":"2025090312090735000_8.2.e002422.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021736"},{"key":"2025090312090735000_8.2.e002422.7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jimd.12363","article-title":"Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients","volume":"44","author":"Ranganath","year":"2021","journal-title":"J Inherit Metab Dis"},{"key":"2025090312090735000_8.2.e002422.8","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S2213-8587(20)30228-X","article-title":"Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial","volume":"8","author":"Ranganath","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025090312090735000_8.2.e002422.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.07.011"},{"key":"2025090312090735000_8.2.e002422.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206033"},{"key":"2025090312090735000_8.2.e002422.11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes396"},{"key":"2025090312090735000_8.2.e002422.12","first-page":"2280","article-title":"Musculoskeletal findings and disability in alkaptonuria","volume":"33","author":"Perry","year":"2006","journal-title":"J Rheumatol"},{"key":"2025090312090735000_8.2.e002422.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7580.2012.01551.x"},{"key":"2025090312090735000_8.2.e002422.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2011.04.016"},{"key":"2025090312090735000_8.2.e002422.15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.spinee.2006.06.399","article-title":"Alcaptonuria with lumbar disc prolapse: case study and review of the literature","volume":"7","author":"Kalevski","year":"2007","journal-title":"Spine J"},{"key":"2025090312090735000_8.2.e002422.16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/sj.sc.3100562","article-title":"Alkaptonuria presenting as lumbar disc prolapse: case report and review of literature","volume":"36","author":"Reddy","year":"1998","journal-title":"Spinal Cord"},{"key":"2025090312090735000_8.2.e002422.17","first-page":"45","article-title":"The nutritional status of people with alkaptonuria: an exploratory analysis suggests a protein\/energy dilemma","volume":"53","author":"Judd","year":"2020","journal-title":"JIMD Rep"},{"key":"2025090312090735000_8.2.e002422.18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/jimd.12181","article-title":"Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria","volume":"43","author":"Ranganath","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"2025090312090735000_8.2.e002422.19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jimd.12172","article-title":"Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria","volume":"43","author":"Hughes","year":"2020","journal-title":"J Inherit Metab Dis"},{"key":"2025090312090735000_8.2.e002422.20","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.hmg.a018927"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:09:13Z","timestamp":1756926553000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/rmdopen-2022-002422"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002422","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}